Table 2.
Subgroup analysis of pooled HR for OS
| Categories | No. of studies | No. of patients | Pooled HR (95%CI) | Heterogeneity | ||
|---|---|---|---|---|---|---|
| Fix/Random | P-value | I2 (%) | P-value | |||
| OS | 13 | 2272 | 2.33 (1.76, 3.09) | 0 | 63.4 | 0.001 |
| Cancer type | 8 | |||||
| Colorectal cancer | 3 | 834 | 1.79 (1.35, 2.37) | 0 | 0 | 0.499 |
| Pancreatic cancer | 2 | 172 | 2.98 (1.95, 4.55) | 0 | 0 | 0.391 |
| Gastric cancer | 2 | 119 | 2.76 (0.48, 15.84) | 0.256 | 59.9 | 0.114 |
| Urothelial bladder cancer | 2 | 443 | 2.14 (1.48, 3.10) | 0 | 0 | 0.880 |
| Other cancers | 4 | 704 | 2.60 (1.45, 4.66) | 0.001 | 83.3 | 0 |
| Analysis | ||||||
| K-M curve | 4 | 355 | 1.85 (1.17, 2.95) | 0.009 | 0 | 0.89 |
| Multivariate | 9 | 2017 | 2.59 (1.77, 3.80) | 0 | 74.7 | 0 |
| Antibody type | ||||||
| Monoclonal antibody | 2 | 157 | 2.25 (1.36, 3.73) | 0.002 | 0 | 0.975 |
| Polyclonal antibody | 6 | 1672 | 2.55 (1.45, 4.50) | 0.001 | 0 | 81.6 |
| M + P | 2 | 443 | 2.14 (1.48, 3.10) | 0 | 0 | 0.880 |
| Ethnicity | ||||||
| European | 6 | 1361 | 1.84 (1.47, 2.30) | 0 | 0 | 0.834 |
| Asian | 6 | 730 | 3.49 (2.02, 6.02) | 0 | 64.5 | 0.015 |
| North American | 1 | 181 | 1.67 (1.23, 2.29) | – | – | |
| Sample size | ||||||
| < 150 | 8 | 628 | 2.46 (1.81, 3.33) | 0 | 0 | 0.536 |
| ≥150 | 5 | 1644 | 2.36 (1.53, 3.65) | 0 | 81.3 | 0 |
OS overall survival, HR hazard ratio